Skip to main content
. 2020 Jun 24;10(6):954. doi: 10.3390/biom10060954

Figure 4.

Figure 4

Tmprss2 as a drug target. (A) The surface representation of the SARS-CoV2 Tmprss2. The catalytic site is shown in blue, and the catalytic residue Ser441 is shown in yellow. (B–D) Molecular docking of famotidine, camostat and nafamostat, respectively, into the catalytic site of Tmprss2. The 3D structures of the protein–drug complexes are shown on the left. The protein is represented in ribbon, and drug ligands are shown as sticks. Famotidine is shown in dark blue, while camostat and nafamostat are shown in orange. The main interacting residues are also indicated. The 2D diagrams of the main interaction networks between the drug ligand and the residues within the protease active site are shown on the right. The specific types of interactions are indicated in the legend. The final 3D structures and 2D diagrams of the protein–drug complexes were visualized with the Biovia Discovery Studio Visualizer 17.2.0 software.